Alzheimer's Disease International (ADI). World Alzheimer Report 2019: Attitudes to dementia. https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf. Accessed 27 May 2022.
Alzheimer's Association. 2021 Alzheimer’s disease facts and figures. Alzheimers Dement. 2021;17:327–406.
Article
CAS
Google Scholar
Cavazzoni P. FDA’s decision to approve new treatment for Alzheimer’s disease. https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease. Accessed 31 Mar 2022.
Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, et al. Aducanumab: Appropriate use recommendations. J Prev Alzheimers Dis. 2021;8:398–410.
Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement (N Y). 2020;6:e12050.
Google Scholar
Dubois B, Padovani A, Scheltens P, Rossi A, Dell'Agnello G. Timely diagnosis for Alzheimer’s disease: A literature review on benefits and challenges. J Alzheimers Dis. 2016;49:617–31.
Article
PubMed
Google Scholar
Glaab E, Rauschenberger A, Banzi R, Gerardi C, Garcia P, et al. Biomarker discovery studies for patient stratification using machine learning analysis of omics data: A scoping review. BMJ Open. 2021;11:e053674.
Article
PubMed
PubMed Central
Google Scholar
Young AL, Marinescu RV, Oxtoby NP, Bocchetta M, Yong K, et al. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with subtype and stage inference. Nat Commun. 2018;9:4273.
Article
PubMed
PubMed Central
CAS
Google Scholar
Barton A, Pitzalis C. Stratified medicine in rheumatoid arthritis-the MATURA programme. Rheumatology (Oxford). 2017;56:1247–50.
Article
Google Scholar
Cousins H, Cousins C. A framework for patient stratification in clinical trials for Alzheimer’s disease. J Alzheimers Neurodegener Dis. 2020;6:033.
Article
Google Scholar
Cerezo Cerezo J, Arias López C. Population stratification: A fundamental instrument used for population health management in Spain: good practice brief. https://apps.who.int/iris/handle/10665/345586. Accessed 31 Mar 2022.
Coran JJ, Schario ME, Pronovost PJ. Stratifying for value: An updated population health risk stratification approach. Popul Health Manag. 2022;25:91–9.
Article
PubMed
Google Scholar
Russnes HG, Lingjærde OC, Børresen-Dale AL, Caldas C. Breast cancer molecular stratification: From intrinsic subtypes to integrative clusters. Am J Pathol. 2017;187:2152–62.
Article
CAS
PubMed
Google Scholar
American Cancer Society. Breast cancer facts & figures 2019-20. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf. Accessed 31 Mar 2022.
Ying L, Yan F, Xu D. Cancer patient stratification based on the tumor microenvironment. J Thorac Dis. 2020;12:4522–6.
Article
PubMed
PubMed Central
Google Scholar
Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, et al. Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group. Lancet Neurol. 2021;20:484–96.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, et al. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62.
Ferretti MT, Martinkova J, Biskup E, Benke T, Gialdini G, et al. Sex and gender differences in Alzheimer's disease: current challenges and implications for clinical practice: Position paper of the dementia and cognitive disorders panel of the European Academy of Neurology. Eur J Neurol. 2020;27:928–43.
Seidl JN, Massman PJ. Rapidly versus slowly progressing patients with Alzheimer’s disease: Differences in baseline cognition. Am J Alzheimers Dis Other Dement. 2016;31:318–25.
Liu J, Hlávka J, Hillestad R, Mattke S. Assessing the preparedness of the US health care system infrastructure for an Alzheimer’s treatment: RAND Corporation; 2017. Online only:1-16.
Reitz C. Toward precision medicine in Alzheimer’s disease. Ann Transl Med. 2016;4:107.
Article
PubMed
PubMed Central
CAS
Google Scholar
Li JQ, Tan L, Wang HF, Tan MS, Tan L, et al. Risk factors for predicting progression from mild cognitive impairment to Alzheimer’s disease: a systematic review and meta-analysis of cohort studies. J Neurol Neurosurg Psychiatry. 2016;87:476–84.
Article
PubMed
Google Scholar
Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: Meta-analysis. Acta Psychiatr Scand. 2014;130:439–51.
Gulpers B, Ramakers I, Hamel R, Köhler S, Voshaar RO, et al. Anxiety as a predictor for cognitive decline and dementia: A systematic review and meta-analysis. Am J Geriatr Psychiatry. 2016;24:823–42.
Article
PubMed
Google Scholar
Espinosa A, Alegret M, Valero S, Vinyes-Junqué G, Hernández I, et al. A longitudinal follow-up of 550 mild cognitive impairment patients: Evidence for large conversion to dementia rates and detection of major risk factors involved. J Alzheimers Dis. 2013;34:769–80.
Article
PubMed
Google Scholar
Espinosa A, Alegret M, Pesini P, Valero S, Lafuente A, et al. Cognitive composites domain scores related to neuroimaging biomarkers within probable-amnestic mild cognitive impairment-storage subtype. J Alzheimers Dis. 2017;57:447–59.
Article
CAS
PubMed
PubMed Central
Google Scholar
Risacher SL, Saykin AJ. Neuroimaging biomarkers of neurodegenerative diseases and dementia. Semin Neurol. 2013;33:386–416.
Article
PubMed
PubMed Central
Google Scholar
Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019;15:888–98.
Article
PubMed
PubMed Central
Google Scholar
Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396:413–46.
Article
PubMed
PubMed Central
Google Scholar
Hampel H, Vergallo A, Giorgi FS, Kim SH, Depypere H, et al. Precision medicine and drug development in Alzheimer’s disease: the importance of sexual dimorphism and patient stratification. Front Neuroendocrinol. 2018;50:31–51.
Article
PubMed
Google Scholar
Hlávka JP, Mattke S, Liu JL. Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer’s treatment. Rand Health Q. 2019;8:2.
PubMed
PubMed Central
Google Scholar
National Collaborating Centre for Mental Health. The Dementia Care Pathway. https://www.rcpsych.ac.uk/docs/default-source/improving-care/nccmh/dementia/nccmh-dementia-care-pathway-full-implementation-guidance.pdf?sfvrsn=cdef189d_8. Accessed 31 Mar 2022.
Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6:67–77.
Article
PubMed
PubMed Central
Google Scholar
Niemantsverdriet E, Valckx S, Bjerke M, Engelborghs S. Alzheimer’s disease CSF biomarkers: Clinical indications and rational use. Acta Neurol Belg. 2017;117:591–602.
Article
PubMed
PubMed Central
Google Scholar
Nordberg A, Rinne JO, Kadir A, Långström B. The use of PET in Alzheimer disease. Nat Rev Neurol. 2010;6:78–87.
Article
CAS
PubMed
Google Scholar
Veiga S, Rodríguez-Martín A, Garcia-Ribas G, Arribas I, Menacho-Román M, et al. Validation of a novel and accurate ApoE4 assay for automated chemistry analyzers. Sci Rep. 2020;10:2138.
Article
CAS
PubMed
PubMed Central
Google Scholar
Calil V, Elliott E, Borelli WV, Barbosa B, Bram J, et al. Challenges in the diagnosis of dementia: Insights from the United Kingdom-Brazil Dementia Workshop. Dement Neuropsychol. 2020;14:201–8.
Article
PubMed
PubMed Central
Google Scholar
Office for National Statistics (ONS). Overview of the UK population: January 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/articles/overviewoftheukpopulation/january2021. Accessed 31 Mar 2022.
AARP. The Aging Readiness & Competitiveness Report. https://arc.aarpinternational.org/countries/brazil. Accessed 31 Mar 2022.
Bullain S, Doody R. What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti-amyloid trials. J Neurochem. 2020;155:120–36.
Article
CAS
PubMed
Google Scholar
Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairns NJ, et al. Understanding disease progression and improving Alzheimer’s disease clinical trials: Recent highlights from the Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement. 2019;15:106–52.
Article
PubMed
Google Scholar
Arighi A, Carandini T, Mercurio M, Carpani G, Pietroboni AM, et al. Word and picture version of the free and cued selective reminding test (FCSRT): Is there any difference? J Alzheimers Dis. 2018;61:47–52.
Article
PubMed
Google Scholar
Boada M, Ristic S, Pross N, Abi-Saab D, Bullain S, et al. Trial design of the GRADUATE studies: Phase III, randomized, placebo-controlled studies evaluating gantenerumab in patients with early Alzheimer’s disease. Clin Neurophysiol. 2019;130:Abstract P37.
Article
Google Scholar
Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384:1691–704.
Article
CAS
PubMed
Google Scholar
Blennow K. A review of fluid biomarkers for Alzheimer’s disease: moving from CSF to blood. Neurol Ther. 2017;6:15–24.
Article
PubMed
PubMed Central
Google Scholar
Cummings JL, Atri A, Ballard C, Boneva N, Frölich L, et al. Insights into globalization: Comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer’s disease clinical program. Alzheimers Res Ther. 2018;10:116.
Article
PubMed
PubMed Central
CAS
Google Scholar
DiFrancesco JC, Longoni M, Piazza F. Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA): Candidate biomarker for immunotherapy in Alzheimer’s disease and cerebral amyloid angiopathy. Front Neurol. 2015;6:207.
Article
PubMed
PubMed Central
Google Scholar
Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79:13–21.
Article
PubMed
Google Scholar
De Roeck EE, De Deyn PP, Dierckx E, Engelborghs S. Brief cognitive screening instruments for early detection of Alzheimer’s disease: A systematic review. Alzheimers Res Ther. 2019;11:21.
Article
PubMed
PubMed Central
Google Scholar
Brodaty H, Connors MH, Loy C, Teixeira-Pinto A, Stocks N, et al. Screening for dementia in primary care: A comparison of the GPCOG and the MMSE. Dement Geriatr Cogn Disord. 2016;42:323–30.
Article
PubMed
Google Scholar
Papp KV, Rentz DM, Orlovsky I, Sperling RA, Mormino EC. Optimizing the preclinical Alzheimer’s cognitive composite with semantic processing: The PACC5. Alzheimers Dement (N Y). 2017;3:668–77.
Article
Google Scholar
Alves L, Simões MR, Martins C, Freitas S, Santana I. Premorbid IQ influence on screening tests’ scores in healthy patients and patients with cognitive impairment. J Geriatr Psychiatry Neurol. 2013;26:117–26.
Article
PubMed
Google Scholar
Lanoiselée HM, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med. 2017;14:e1002270.
Article
PubMed
PubMed Central
CAS
Google Scholar
Pankiewicz JE, Sadowski MJ. APOE genotype and Alzheimer’s immunotherapy. Oncotarget. 2017;8:39941–2.
Article
PubMed
PubMed Central
Google Scholar
Blazhenets G, Ma Y, Sörensen A, Schiller F, Rücker G, et al. Predictive Value of (18)F-Florbetapir and (18)F-FDG PET for Conversion from Mild Cognitive Impairment to Alzheimer Dementia. J Nucl Med. 2020;61:597–603.
Article
CAS
PubMed
PubMed Central
Google Scholar
Leuzy A, Chiotis K, Lemoine L, Gillberg P-G, Almkvist O, et al. Tau PET imaging in neurodegenerative tauopathies—still a challenge. Mol Psychiatry. 2019;24:1112–34.
Article
CAS
PubMed
PubMed Central
Google Scholar
Filippi L, Chiaravalloti A, Bagni O, Schillaci O. (18)F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer’s disease. Am J Nucl Med Mol Imaging. 2018;8:268–81.
CAS
PubMed
PubMed Central
Google Scholar
Suppiah S, Didier M-A, Vinjamuri S. The who, when, why, and how of PET amyloid imaging in management of Alzheimer’s disease—Review of literature and interesting images. Diagnostics (Basel). 2019;9:65.
Article
CAS
Google Scholar
Michaud TL, Kane RL, Riley McCarten J, Gaugler JE, Nyman JA, et al. Risk stratification using cerebrospinal fluid biomarkers in patients with mild cognitive impairment: An exploratory analysis. J Alzheimers Dis. 2015;47:729–40.
Article
CAS
PubMed
PubMed Central
Google Scholar
Budelier MM, Bateman RJ. Biomarkers of Alzheimer disease. J Appl Lab Med. 2020;5:194–208.
Article
PubMed
PubMed Central
Google Scholar
Blennow K, Shaw LM, Stomrud E, Mattsson N, Toledo JB, et al. Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays. Sci Rep. 2019;9:19024.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rabe C, Thorne N, Voyle N, Mertes M, Mellino G, et al. Evaluation of the Elecsys NeuroToolKit panel in early Alzheimer’s disease populations across six clinical trials. Alzheimers Dement. 2021;17:Abstract e052033.
Article
Google Scholar
Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, et al. The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis. Clin Chim Acta. 2021;519:267–75.
Article
CAS
PubMed
Google Scholar
Hale C. C2N debuts Alzheimer's blood test for predicting amyloid plaque deposits in the brain [press release]. 2020. https://www.fiercebiotech.com/medtech/c2n-debuts-alzheimer-s-blood-test-for-predicting-amyloid-plaque-deposits-brain. Accessed 31 Mar 2022.
Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772–81.
Article
CAS
PubMed
Google Scholar
Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, et al. Blood-based biomarkers for Alzheimer disease: Mapping the road to the clinic. Nat Rev Neurol. 2018;14:639–52.
Article
PubMed
PubMed Central
Google Scholar
Park J-C, Jung KS, Kim J, Jang JS, Kwon S, et al. Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition. Alzheimers Res Ther. 2021;13:12.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mattke S, Cho SK, Bittner T, Hlávka J, Hanson M. Blood-based biomarkers for Alzheimer’s pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times. Alzheimers Dement (Amst). 2020;12:e12081.
Google Scholar
Wellington H, Paterson RW, Portelius E, Törnqvist U, Magdalinou N, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86:829–35.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and meta-analysis. JAMA Neurol. 2019;76:1035–48.
Article
PubMed
PubMed Central
Google Scholar
Judge D, Roberts J, Khandker R, Ambegaonkar B, Black CM. Physician perceptions about the barriers to prompt diagnosis of mild cognitive impairment and Alzheimer’s disease. Int J Alzheimers Dis. 2019;2019:3637954.
PubMed
PubMed Central
Google Scholar
Galvin JE, Valois L, Zweig Y. Collaborative transdisciplinary team approach for dementia care. Neurodegener Dis Manag. 2014;4:455–69.
Article
PubMed
Google Scholar
Kühnel L, Bouteloup V, Lespinasse J, Chêne G, Dufouil C, et al. Personalized prediction of progression in pre-dementia patients based on individual biomarker profile: A development and validation study. Alzheimers Dement. 2021;17:1938–49.
Article
PubMed
Google Scholar
Cullen NC, Leuzy A, Janelidze S, Palmqvist S, Svenningsson AL, et al. Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun. 2021;12:3555.
Article
CAS
PubMed
PubMed Central
Google Scholar
Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, et al. Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27:1034–42.
Article
CAS
PubMed
Google Scholar
Biogen Inc. ADUHELM™ (aducanumab-avwa). Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s003lbl.pdf. Accessed 31 Mar 2022.
Grabher BJ. Effects of Alzheimer disease on patients and their family. J Nucl Med Technol. 2018;46:335–40.
Article
PubMed
Google Scholar